Neurocrine’s Chief Commercial Officer’s $36 Option Exercise Signals Insider Confidence as Stock Nears 52‑Week Low
Neurocrine insider buying: CCO Eric Ben Evich purchases 12,830 shares at $35.99, signaling confidence amid a 52‑week low and potential upside for investors.
3 minutes to read